Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 6/20 | 0.48 |
| ▸ | THRA | P10827 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 8/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801926 | 0.95 | SIGMAR1 (0.48) | SIGMAR1S1PR1S1PR2THRATHRB | |
| SCHEMBL6803279 | 0.89 | SIGMAR1 (0.45) | SIGMAR1S1PR1S1PR2THRATHRB | |
| SCHEMBL8553953 | 0.89 | SIGMAR1 (0.45) | SIGMAR1S1PR1S1PR2THRATHRB | |
| SCHEMBL6802005 | 0.80 | KDM4E (0.42) | SIGMAR1 | |
| SCHEMBL27529199 | 0.79 | S1PR1 (0.61) | S1PR1S1PR2THRATHRBSPHK1 | |
| SCHEMBL6807963 | 0.79 | S1PR2 (0.54) | S1PR1S1PR2THRATHRBSPHK1 | |
| SCHEMBL6801564 | 0.79 | S1PR2 (0.54) | S1PR1S1PR2THRATHRBSPHK1 | |
| SCHEMBL6803100 | 0.79 | SIGMAR1 (0.46) | SIGMAR1 | |
| SCHEMBL6796677 | 0.78 | HPGD (0.40) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL6803661 | 0.78 | S1PR1 (0.59) | S1PR1S1PR2THRATHRBSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | FUKAMI NAOKI (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2002-11-14 | — | — | US | disclosed |
| EP-0854863-B1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | SIGMAR1 2194/4885S1PR1 355/4885S1PR2 282/4885 |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | PLA2G4A, PLA2G4B, PLA2G1B | SIGMAR1 1749/4885S1PR1 252/4885S1PR2 240/4885 |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | SIGMAR1 1951/4885S1PR1 307/4885S1PR2 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.